Specificity Trial of the Recombinant Tuberculosis Allergen in BCG Vaccinated Healthy Volunteers

Tuberculosis Clinical Trial

Official title:

Evaluation of the Specificity of Intradermal Test With Recombinant Tuberculosis Allergen in BCG Vaccinated Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05203068
• Other study ID #: 102/1
• Status: Completed
• Phase: N/A
• Start date: November 24, 2021
• Est. completion date: January 26, 2022

Study information

• Verified date: October 2022
• Source: National Medical Research Center of Phthisiopulmonology and Infectious Diseases
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to test the recombinant tuberculosis skin test in the previously BCG vaccinated healthy adults with low risk of TB development, to determine the test specificity.

Description:

Recombinant tuberculosis allergen (RTA) is a recombinant fusion protein CFP10-ESAT6 produced by the prokaryotic cell line. The test is widely used in Russian Federation and CIS countries for the latent TB diagnosis in adults and children over 8 years old. The current clinical study is a prospective, multicenter, open-label study in the cohort of healthy adults, not classified as at risk of tuberculosis, with no clinical symptoms of the disease, with a negative T-SPOT.TB test results, to evaluate the specificity of the RTA test in 72 hours following administration of the product at a dose of 0.2 μg/0.1 mL.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: January 26, 2022
• Est. primary completion date: January 18, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

1. Signed informed consent for the participation in the study.

2. Age 18 to 30 years

3. A history of BCG vaccination (confirmed by medical documentation and/or the presence of BCG scar)

4. Healthy individual according to physical examination and medical records at screening.

5. Willingness to cooperate and follow the recommendations of the Investigator in accordance with the Protocol.

Exclusion Criteria:

1. A history of tuberculosis or close contact with a patient with active tuberculosis for 5 years prior to the enrollment in the study.

2. Positive T-SPOT.TB test at the enrollment in the study

3. Treatment with drugs affecting immune system within 3 months prior to the enrollment in the study

4. Vaccination against any infections <1.5 months prior to the enrollment in the study

5. Vaccination with BCG <6 months prior to the enrollment in the study.

6. The Mantoux test with 2 TU and/or the test with the recombinant tuberculosis allergen was performed less than 6 months prior to the enrollment in the study.

7. Congenital or acquired immunodeficiency.

8. Active disease of the immune system

9. HIV infection.

10. The current condition of the skin interferes with the conduct and reading of skin tests (trauma, skin diseases).

11. A disease in which blood sampling poses a risk to the volunteer (hemophilia, other bleeding disorders) or obstructed venous access.

12. The volunteer currently participates in another clinical study or has participated in another clinical study within 3 months prior to the enrollment in the study.

13. Previous participation in clinical studies of ESAT-6 and/or CFP-10 antigens.

14. Pregnancy, lactation, pregnancy planning.

15. The reluctance of a female person to use effective barrier (including spermicidal gel), hormonal or intrauterine contraceptives during the study.

16. History of alcohol, drug, benzodiazepine, or other substance abuse within the 12 months prior to the enrollment in the study.

17. Use of alcoholic beverages within 24 hours prior to the visit.

18. A condition or disease that, in the opinion of the Investigator, is inappropriate for participation in the study.

Related Conditions & MeSH terms

• Tuberculosis

Intervention

Diagnostic Test:
• Recombinant tuberculosis allergen (RTA)
Single intradermal application of 0.2 µg/0.1 mL RTA (CFP10-ESAT6) in the middle of the forearm

Locations

Country	Name	City	State
Russian Federation	National Medical Research Center of Phthisiopulmonology and Infectious Diseases	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
National Medical Research Center of Phthisiopulmonology and Infectious Diseases

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of the Volunteers With the True Negative RTA Result	Absolute number and percentage of the volunteers with negative and positive test results with RTA based on the results of the assessment of the infiltrate 72 hours after the test application	hour 72
Secondary	Number of Subjects With Local Adverse Reactions Within 72 Hours Following the Intradermal Test Application	To assess the number of subjects who developed the injection site adverse reaction (redness, swelling etc) within 72 hours after RTA test application	hour 72
Secondary	Number of Participants With General and Local Adverse Reactions Within 28 Days After Administration of RTA	To assess the number of subjects who developed the general adverse reaction (e.g. infections, fever, headache, weakness etc) based on the subjects complaints and physical examination, and local injection site reaction (redness, swelling etc) up to 28 days after intradermal RTA application.	Day 28